Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GRK4 Polymorphisms Blood Pressure Response to Candesartan

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by Third Military Medical University
Sponsor:
Information provided by (Responsible Party):
Yu Changqing, Third Military Medical University
ClinicalTrials.gov Identifier:
NCT01629225
First received: June 24, 2012
Last updated: November 17, 2014
Last verified: June 2013
  Purpose

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.


Condition Intervention Phase
Essential Hypertension
Drug: Candesartan
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Third Military Medical University:

Primary Outcome Measures:
  • The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension [ Time Frame: two years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 500
Study Start Date: July 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: candesartan
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
Drug: Candesartan
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Other Name: GRK4 polymorphisms and essential hypertrension

Detailed Description:

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

  Eligibility

Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • men and women with mild to moderate essential hypertension in southwestern Han Chinese

Exclusion Criteria:

  • subjects unwilling to participate or subjects did not have all measurement required,
  • subjects who were on medications, which affect blood pressure or
  • whose DNA failed to amplify and 8 with errors in Mendelian segregation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01629225

Contacts
Contact: Yu changqing, Doctor 02368731850 changqingyu-2@163.com

Locations
China
Department of Cardiology, Daping Hospital, The Third Military Medical University Recruiting
Chongqing, China, 400042
Contact: Yu Changqing, MD       changqingyu-2@163.com   
Sponsors and Collaborators
Third Military Medical University
Investigators
Study Director: Zeng Chunyu, Doctor TMMU
  More Information

No publications provided

Responsible Party: Yu Changqing, Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;, Third Military Medical University
ClinicalTrials.gov Identifier: NCT01629225     History of Changes
Other Study ID Numbers: ThirdMMU
Study First Received: June 24, 2012
Last Updated: November 17, 2014
Health Authority: China: Food and Drug Administration

Keywords provided by Third Military Medical University:
men and women
in southwestern Han Chinese

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases
Candesartan
Candesartan cilexetil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014